The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:
----------
Premier African Minerals Ltd - Africa-focused metals and mineral project developer - Launches subscription to raise £2.4 million via the issue of shares at 0.23 pence each. Says the placing will be used to fund its Zulu lithium and tantalum project. Adds that it expects revenue generating production by February 2024, after it installs a 55 tonnes per hour bar mill by early February. Adds that it has settled a $2.5 million payment via the issue of 769.2 million shares. Chief Executive George Roach says: ‘The subscription and the contractor settlement should see Zulu through to production in February 2024. We are deeply encouraged that the subscription was taken up by two institutional investors with one of the investors having supported the company previously. We believe that the attraction of further institutional investment into Premier demonstrates the underlying value of Premier.’
----------
Angle PLC - Surrey, England-based medical diagnostics company - Says University of New Mexico researchers using its Parsortix system to harvest circulating tumour cells for analysis said: ‘gene expression in CTCs could be pivotal to prescribing more targeted treatment based on the needs of the patient.’ Says the research proves that Parsortix has the capability to harvest CTCs for analysis. Says the system was used to harvest the cells for testing two cancer drugs in pre-clinical mouse models. CEO Andrew Newland comments: ‘The use of CTC biomarkers in clinical trials is a rapidly growing field enabling longitudinal monitoring of transcriptomic and proteomic changes. Angle can provide pharma customers with a complete range of services to support preclinical and clinical drug development. This includes standardised and validated protocols for analysing CTCs including the established techniques of IF, dPCR and NGS, and the capability to deliver bespoke assays to identify drug targets and ascertain therapeutic efficacy.’
----------
Thor Energy PLC - US and Australia-focused mineral exploration company - Says metallurgical copper recovery results from its Alford East copper project show recovery up to 72.2% using glycine lixiviant, which is benign and environmentally friendly. CEO Nicole Galloway Warland says: ‘The successful completion of the hydrometallurgical mini-column tests; returning favourable copper recoveries of up to 72.2% are above the standard range of 60-70% for an [in-situ recovery] operation. These results are highly encouraging, as Thor advances the ISR assessment of the Alford East Copper-REE-Gold Project. As part of Thor’s commitment to sustainable exploration activities, we are pleased to be using Glyleach TM as a lixiviant during the ISR process. Compared to the conventional sulphuric acid that is often used, Glyleach TM is an economical and environmentally friendly alternative, helping Thor to develop a low-cost, low-environmental footprint ISR copper operation.
----------
Blencowe Resources PLC - London-based graphite miner operating the Orom-Cross project in northern Uganda - Says it has completed excavation and preparation at Orom-Cross for the export of an additional 600 tonne bulk sample. Notes that the sample will be shipped to the Jilian New Technology pilot plant facility in China for processing. Adds that the sample will be used to confirm the consistency of its end products. Says test work on sustainable tailings disposal options is nearing completion. Adds that it is proceeding with additional test work for other specialised market segments. Chair Cameron Pearce comments: ’Blencowe is making progress on all parts of the Definitive Feasibility Study with key actions currently underway in Uganda, China, Australia and the United States respectively. We are very pleased with all results to date and we will continue to add value to this world class project.‘
----------
Ondine Biomedical Inc - Vancouver-based life sciences company - Says it has raised £2.9 million via a placing. Says it will issue a further 1.1 million new shares at 9 pence each, representing a 9% premium to the closing price at November 29. Says it will use the proceeds to support its commercialisation in Canada, the UK, Spain and Mexico, and will provide a cash runway until at least the middle of the second quarter in 2024.
----------
Copyright 2023 Alliance News Ltd. All Rights Reserved.
